The short answer: ibogaine is illegal to possess or administer in the United States, where it sits on Schedule I of the Controlled Substances Act, and it is unscheduled in Mexico, where clinics operate openly. That legal gap is the entire reason a treatment industry exists across the border.
Ibogaine does not appear in Article 245 of Mexico's Ley General de Salud, the schedule of controlled psychotropic substances. It is therefore not a crime to possess or administer it. But unscheduled is not the same as approved: COFEPRIS, Mexico's health regulator, has not authorized ibogaine as a medicine, and there is no ibogaine-specific licensing regime for clinics. The practical consequence is that quality control is entirely up to the operator, which is why clinic vetting matters so much more than it would in a regulated system.
Ibogaine has been Schedule I federally since the early 1970s, classed as having high abuse potential and no accepted medical use. Researchers have long disputed that classification, and the policy ground is moving. In 2025, seven states introduced ibogaine research or access legislation, per the Legislative Analysis and Public Policy Association. Texas went furthest: a $50 million state fund, awarded in December 2025 to UTMB Health and UTHealth Houston, is running a multicenter FDA-track trial called IMPACT covering addiction, PTSD and traumatic brain injury. None of this changes the law for patients today, but it explains why interest keeps climbing.
Traveling to Mexico for treatment is how essentially all American ibogaine patients do it, including the veterans in the Stanford study, whose researchers followed patients to a Mexican clinic precisely because US law prevented domestic treatment. Buying ibogaine online or attempting self-treatment in the US is both a federal crime and, more importantly, the highest-risk way to use a cardiotoxic substance. If you are considering treatment, the safest legal path is a vetted Mexican clinic with real medical infrastructure.